Ahrens Brenton Karl 4
4 · Iterum Therapeutics plc · Filed Mar 29, 2022
Insider Transaction Report
Form 4
Ahrens Brenton Karl
Director
Transactions
- Award
Stock Option (Right to Buy)
2022-03-25+47,436→ 47,436 totalExercise: $0.45Exp: 2032-03-26→ Ordinary Shares (47,436 underlying)
Footnotes (1)
- [F1]Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the shares subject to this option shall vest on January 1, 2023.